Date:	22/04/2021
Your Name	:Kang Li
Manuscript	Title: Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway
Manuscrint	number (if known): ATM-21-2072

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Comment for attending	News	
7	Support for attending meetings and/or travel	None	
	meetings and/or travei		
	Data at a standard in a	Nigor	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date <u>:</u>	22/04/2021		
Your Name	:Junye Chen		
Manuscript	Title: Irisin ameliorates nicotir	ne-mediated atherosclerosis via inhibition of the PI3K pathway	
Manuscript	number (if known):	ATM-21-2072	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
_	David distribution on a Data	News	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004)

Please place an "X" next to the following statement to indicate your agreement:

Date:	_22/04/2021		
Your Name	e:Chaonan	Wang	
Manuscrip	t Title: Irisin ar	neliorates nicotine-mediate	d atherosclerosis via inhibition of the PI3K pathway
Manuscrip	t number (if knov	wn): ATM-21-2072	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Comment for attending	News	
7	Support for attending meetings and/or travel	None	
	meetings and/or travei		
	Data at a standard translation	Nigor	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date <u>:</u>	22/04/2021	
Your Name	ne:Jiang Shao	
Manuscript	ipt Title: Irisin ameliorates nicotine-mediated atherosclerosis v	ia inhibition of the PI3K pathway
Manuscript	ipt number (if known): ATM-21-2072	•

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Comment for attending	News	
7	Support for attending meetings and/or travel	None	
	meetings and/or travei		
	Data at a standard in a	Nigor	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date:	22/04/2021
Your Name	e: Zhichao Lai
Manuscrip	t Title: Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway
Manuscrin	t number (if known): ATM-21-2072

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	5 5 .		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10		Nama	
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services	_	
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date:	_22/04/2021
Your Name	e:Xiaoxi Yu
Manuscrip	t Title: Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway
Manuscrin	t number (if known): ATM-21-2072

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Comment for attending	News	
7	Support for attending meetings and/or travel	None	
	meetings and/or travei		
	Data at a standard in a standard	Nigor	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date <u>:</u>	22/04/2021		
Your Name	:Fenghe Du		
Manuscript	Title: Irisin ameliorates nico	otine-mediated atherosclerosis via inhibition of the PI3K pathway	
Manuscript	number (if known):	ATM-21-2072	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Comment for attending	News	
7	Support for attending	None	
	meetings and/or travel		
	Data at a standard in a standard	Nigor	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date:	22/04/2021
Your Name	e:Ran Gao
Manuscript	t Title: Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway
Manuscript	t number (if known): ATM-21-2072

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date <u>:</u>	22/04/2021	
Your Name	:Jing Wang	
Manuscript	t Title: Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathwa	y
Manuscript	number (if known): ATM-21-2072	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Comment for attending	News	
7	Support for attending meetings and/or travel	None	
	meetings and/or travei		
	Data at a standard in a	Nigor	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement:

Date: 22/04/2021			
Your Name: Bao Liu			
Manuscript Title: Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway			
Manuscript number (if known): ATM-21-2072			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	l		
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China [grant number 82070498]	no conflicts of interest
	medical writing, article processing charges, etc.) No time limit for this item.	Non-profit Central Research Institute Fund of Chinese Academy Of Medical Science [grant number 2019XK320004]	no conflicts of interest
		the Natural Science Foundation of Beijing Municipality [No. 7182131]	no conflicts of interest
		the Fundamental Research Funds for the Central Universities [No. 3332019129]	no conflicts of interest
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Comment for attending	News	
7	Support for attending meetings and/or travel	None	
	meetings and/or travei		
	Data at a standard translation	Nigor	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this study received funding from the National Natural Science Foundation of China (No. 82070498), the Natural Science Foundation of Beijing Municipality (No. 7182131), the Fundamental Research Funds for the Central Universities (No. 3332019129), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2019XK320004).

Please place an "X" next to the following statement to indicate your agreement: